Antidiabetic Activity of Mangosteen (Garcinia Mangostana L.) Peel Extract Nanoemulsion on Reducing Glucose Levels, Liver Function (SGOT-SGPT) and Liver Histopathology in Male Rats

Abstract

If not properly controlled, diabetes can lead to serious complications, including hypertension, diabetic neuropathy, kidney disease, heart disease, stroke, and liver disorders. SGOT and SGPT are two types of enzymes produced by liver cells, used to examine liver function. This study was conducted to determine the antidiabetic activity of mangosteen (Garcinia mangostana L.) rind extract nanoemulsion on reducing glucose levels and liver function (SGOT-SGPT) and liver histopathology in male rats.The sample of mice used was 24 in 4 groups (control, treatment 1, 2 and 3) where the extract preparation in the treatment was in the form ofnanoemulsion of skin extractmangosteen peel extract (Garcinia Mangostana L)onconcentrations of F1 (1%), F2 (2%), and F3 (3%).OnThe average examination of the levels of KGD, SGOT-SGPT in rats that had diabetes mellitus and were given mangosteen peel extract at a concentration of 1% KGD was 124.3 mg/dL, SGOT 93.1 U/L and SGPT 26.5 U/L. At a concentration of 2% KGD was 94.5 mg/dL, SGOT 75.8 U/L and SGPT 21.1 U/L. At a concentration of 3% KGD was 80.1 mg/Dl, SGOT 52.8 U/L and SGPT 18.5 U/L. In liver histopathologyThe best result group was in treatment group 3 (P3) which was given a 3% concentration of mangosteen peel extract nanoemulsion.